Literature DB >> 17183611

Anti-OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses.

Carl E Ruby1, William L Redmond, Daniel Haley, Andrew D Weinberg.   

Abstract

There is growing evidence that engagement of OX40 (CD134), a member of the TNF receptor superfamily, can directly stimulate antigen-specific CD8+ T cells. It has been shown that CD8+ T cells express OX40 following activation, but the response of antigen-specific CD8+ T cells to OX40 stimulation has not been fully characterized. We utilized an antigen-specific transgenic CD8+ T cell model (OT-I) to determine if OX40 engagement can boost the generation of antigen-specific CD8+ T cell memory. Our results demonstrate that enhanced OX40 costimulation, via an agonist anti-OX40 antibody, increases CD25 and phospho-Akt expression on the antigen-specific CD8+ T cells and significantly increases the generation of long-lived antigen-specific CD8+ memory T cells. The increased numbers of memory CD8+ T cells generated via anti-OX40 treatment still required the presence of CD4+ T cells for their long-term maintenance in vivo. In addition, anti-OX40 costimulation greatly enhanced antigen-specific CD8+ T cell recall responses. These data show that OX40 engagement in vivo increases the number of antigen-specific CD8+ memory T cells surviving after antigen challenge and has implications for the development of more potent vaccines against pathogens and cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17183611     DOI: 10.1002/eji.200636428

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  45 in total

Review 1.  Signaling through OX40 enhances antitumor immunity.

Authors:  Shawn M Jensen; Levi D Maston; Michael J Gough; Carl E Ruby; William L Redmond; Marka Crittenden; Yuhuan Li; Sachin Puri; Christian H Poehlein; Nick Morris; Magdalena Kovacsovics-Bankowski; Tarsem Moudgil; Chris Twitty; Edwin B Walker; Hong-Ming Hu; Walter J Urba; Andrew D Weinberg; Brendan Curti; Bernard A Fox
Journal:  Semin Oncol       Date:  2010-10       Impact factor: 4.929

2.  A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment.

Authors:  Angela D Pardee; Dustin McCurry; Sean Alber; Peisheng Hu; Alan L Epstein; Walter J Storkus
Journal:  Cancer Res       Date:  2010-11-02       Impact factor: 12.701

3.  Histone acetyltransferase CBP is critical for conventional effector and memory T-cell differentiation in mice.

Authors:  Ann R Piccirillo; Richard T Cattley; Louise M D'Cruz; William F Hawse
Journal:  J Biol Chem       Date:  2018-12-20       Impact factor: 5.157

Review 4.  Science gone translational: the OX40 agonist story.

Authors:  Andrew D Weinberg; Nicholas P Morris; Magdalena Kovacsovics-Bankowski; Walter J Urba; Brendan D Curti
Journal:  Immunol Rev       Date:  2011-11       Impact factor: 12.988

5.  CD134-allodepletion allows selective elimination of alloreactive human T cells without loss of virus-specific and leukemia-specific effectors.

Authors:  Xupeng Ge; Julia Brown; Megan Sykes; Vassiliki A Boussiotis
Journal:  Biol Blood Marrow Transplant       Date:  2008-05       Impact factor: 5.742

6.  Interruption of OX40L signaling prevents costimulation blockade-resistant allograft rejection.

Authors:  William H Kitchens; Ying Dong; David V Mathews; Cynthia P Breeden; Elizabeth Strobert; Maria E Fuentes; Christian P Larsen; Mandy L Ford; Andrew B Adams
Journal:  JCI Insight       Date:  2017-03-09

7.  TNF superfamily receptor OX40 triggers invariant NKT cell pyroptosis and liver injury.

Authors:  Peixiang Lan; Yihui Fan; Yue Zhao; Xiaohua Lou; Howard P Monsour; Xiaolong Zhang; Yongwon Choi; Yaling Dou; Naoto Ishii; Rafik M Ghobrial; Xiang Xiao; Xian Chang Li
Journal:  J Clin Invest       Date:  2017-04-24       Impact factor: 14.808

8.  Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein.

Authors:  Michael D Oberst; Catherine Augé; Chad Morris; Stacy Kentner; Kathy Mulgrew; Kelly McGlinchey; James Hair; Shino Hanabuchi; Qun Du; Melissa Damschroder; Hui Feng; Steven Eck; Nicholas Buss; Lolke de Haan; Andrew J Pierce; Haesun Park; Andrew Sylwester; Michael K Axthelm; Louis Picker; Nicholas P Morris; Andrew Weinberg; Scott A Hammond
Journal:  Mol Cancer Ther       Date:  2018-03-15       Impact factor: 6.261

Review 9.  Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges.

Authors:  Chrisann Kyi; Michael A Postow
Journal:  Immunotherapy       Date:  2016-06       Impact factor: 4.196

Review 10.  mTOR, metabolism, and the regulation of T-cell differentiation and function.

Authors:  Adam T Waickman; Jonathan D Powell
Journal:  Immunol Rev       Date:  2012-09       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.